ESMO Breast 2022 | TUXEDO-1: trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastases

Gaia Griguolo, MD, University of Padova, Padova, Italy, discusses the significance of the Phase II TUXEDO-1 trial (NCT04752059) investigating trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastases. A response rate of over 70% was demonstrated, as well as progression-free survival (PFS) rate of over 1 year. Active systemic agents for the treatment of this patient population could enable for the delay of whole-brain radiotherapy and ultimately improve quality of life, in addition to overall survival (OS). This interview took place at the European Society for Medical Oncology (ESMO) Breast Cancer 2022 congress in Berlin, Germany.